title: Association between polymorphisms in selected inflammatory response genes and the risk of prostate cancer.
abstract: Inflammation represents an important event which facilitates prostate carcinogenesis. Genetic variations in inflammatory response genes could affect the level and function of the protein products, resulting in the differential prostate cancer risk among carriers of different variants. This study attempted to investigate the association of IL-4 rs2243250, IL-6 rs10499563, IL-8 rs4073, as well as NFKBIA rs2233406 and rs3138053 polymorphisms with prostate cancer risk in the Chinese population. Genotyping of the polymorphisms was performed by using polymerase chain reaction-restriction fragment length polymorphism technique on 439 prostate cancer patients and 524 controls, and the association of each polymorphic genotype with prostate cancer risk was evaluated by using logistic regression analysis based on allele, heterozygous, and homozygous comparison models, with adjustment to age and smoking status. We showed that the C allele of IL-4 rs2243250 polymorphism could increase prostate cancer risk (heterozygous comparison model: odds ratio [OR] =1.434, 95% confidence interval [CI] =1.092-1.881, P=0.009; homozygous comparison model: OR =2.301, 95% CI =1.402-3.775, P=0.001; allele comparison model: OR =1.509, 95% CI =1.228-1.853, P<0.001). On the other hand, the C allele of rs10499563 polymorphism could decrease prostate cancer risk (heterozygous comparison model: OR =0.694, 95% CI =0.525-0.918, P=0.010; homozygous comparison model: OR =0.499, 95% CI =0.269-0.926, P=0.028; allele comparison model: OR =0.692, 95% CI =0.553-0.867, P=0.001). No association was observed for the other polymorphisms. In conclusion, IL-4 rs2243250 and IL-6 rs10499563 polymorphisms could serve as potential predictive biomarkers for prostate cancer risk in the Chinese population.
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Oncology, Jingdezhen City People's Hospital, Jingdezhen, People's Republic of China.
authors.forename: Xue-Ming
authors.initials: XM
authors.lastname: Ying
authors.affiliation: Department of Urology, Research Institute, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
authors.forename: Xue-Ming
authors.initials: XM
authors.lastname: Huang
authors.affiliation: The Medical School of Nanchang University, School of Public Health, Nanchang, People's Republic of China.
authors.forename: Peng
authors.initials: P
authors.lastname: Huang
authors.affiliation: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China.
authors.forename: Shao-Cong
authors.initials: SC
authors.lastname: Yan
keywords: biomarkers; inflammation; logistic regression; polymorphisms; prostate neoplasm
references.citation: Cancer. 2005 Feb 15;103(4):740-8
references.pmid: 15643599
references.citation: DNA Cell Biol. 2008 Sep;27(9):505-10
references.pmid: 18694328
references.citation: Mol Cell Biol. 1996 May;16(5):2341-9
references.pmid: 8628301
references.citation: Clin Chem. 2008 May;54(5):841-50
references.pmid: 18356242
references.citation: Carcinogenesis. 2009 Nov;30(11):1916-22
references.pmid: 19797428
references.citation: J Allergy Clin Immunol. 2003 Nov;112(5):893-8
references.pmid: 14610476
references.citation: Carcinogenesis. 2010 Oct;31(10):1748-54
references.pmid: 20403914
references.citation: Yale J Biol Med. 2006 Dec;79(3-4):123-30
references.pmid: 17940622
references.citation: Acta Trop. 2007 Mar;101(3):258-65
references.pmid: 17379175
references.citation: Med Oncol. 2013 Dec;30(4):693
references.pmid: 23996241
references.citation: Mol Biol Rep. 2012 Mar;39(3):2831-41
references.pmid: 21681427
references.citation: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5
references.pmid: 10984506
references.citation: Thorax. 2000 Dec;55(12):1023-7
references.pmid: 11083887
references.citation: Prostate. 2000 Jan;42(1):73-8
references.pmid: 10579801
references.citation: Asian Pac J Cancer Prev. 2013;14(12):7467-72
references.pmid: 24460320
references.citation: J Carcinog. 2012;11:7
references.pmid: 22529743
references.citation: Urology. 2000 Oct 1;56(4):671-6
references.pmid: 11018637
references.citation: Prostate. 2006 Jun 15;66(9):996-1004
references.pmid: 16541418
references.citation: CA Cancer J Clin. 2007 Jul-Aug;57(4):190-205
references.pmid: 17626117
references.citation: Eur J Surg Oncol. 2007 May;33(4):504-7
references.pmid: 17174061
references.citation: Am J Public Health. 2010 Apr;100(4):693-701
references.pmid: 19608952
references.citation: Immunol Cell Biol. 2008 Jan;86(1):87-91
references.pmid: 17724457
references.citation: Oncogene. 2011 May 19;30(20):2345-55
references.pmid: 21258401
references.citation: J Exp Med. 1998 Sep 21;188(6):1039-46
references.pmid: 9743522
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
references.pmid: 12598651
references.citation: J Natl Cancer Inst. 2011 Nov 2;103(21):1570-1
references.pmid: 22010173
references.citation: Lancet Oncol. 2004 May;5(5):303-13
references.pmid: 15120667
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Genes Immun. 2003 Sep;4(6):450-4
references.pmid: 12944982
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):923-33
references.pmid: 21430300
references.citation: PLoS One. 2012;7(4):e35078
references.pmid: 22509384